Breaking Finance News

Zacks Investment Research downgraded MacroGenics Inc (NASDAQ:MGNX) to Sell in a report released today.

Yesterday MacroGenics Inc (NASDAQ:MGNX) traded 5.47% higher at $20.74. The company’s 50-day moving average is $23.38 and its 200-day moving average is $27.13. The last stock close price is down -23.58% from the 200-day moving average, compared to the S&P 500 which has decreased -0.04% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 295,283

Zacks Investment Research has downgraded MacroGenics Inc (NASDAQ:MGNX) to Sell in a report released on Wednesday January 11, 2017.

Previously on 12/20/2016, SunTrust reported about MacroGenics Inc (NASDAQ:MGNX) raised the target price from $0.00 to $30.00. At the time, this indicated a possible upside of 0.51%.

See Chart Below

MacroGenics Inc (NASDAQ:MGNX)

MacroGenics Inc has a 52 week low of $14.84 and a 52 week high of $33.30 The company’s market cap is currently $0.

About MacroGenics Inc (NASDAQ:MGNX)

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.